# Regeneron Expects Mid-Teens R&D Expense Growth Rate in 2027

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/45094
Published: 2026-10-30T20:24:07.000Z
Updated: 2026-10-30T20:24:07.000Z
Section: Business

> The company also expects to recognize Sanofi’s $1 billion upfront payment in Q4.

Regeneron Pharmaceuticals expects research and development expenses to rise at a mid-teens rate in 2027 compared with 2026, setting out a higher spending outlook on its third-quarter 2026 earnings call.

The company also expects to recognize Sanofi’s $1 billion upfront payment in Q4.